|
|
|
| home > epc > autumn 2002 > fat redistribution in hiv patients - an opportunity for drug manufacturers? |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
Fat redistribution, or lipodystrophy, is a complicated disorder of adipose (fat) tissue. There are two main classes of lipodystrophy: inherited lipodystrophies (genetically determined) and acquired lipodystrophies (for example HIV-associated). Historically, lipodystrophy was defined as the selective loss of fat from different regions of the body. This definition has changed, at least with regard to HIV-associated lipodystrophy. When being described in relation to HIV pathogenesis, lipodystrophy is now defined as 'selective fat loss or gain, with preserved body cell mass and weight'. In other words, the observation of abnormal peripheral subcutaneous fat wasting or fat accumulation in patients undergoing combination anti-retroviral therapy.
The global market for drug products to treat lipodystrophy is increasing in size. Epidemiology data are currently being collected for this syndrome, and an increasing amount of research is being conducted to determine the underlying causes of lipodystrophic disorders. Through awareness of this ongoing research, pharmaceutical companies can avoid both the potentially damaging impact of specific drug association and niche target patient groups with therapy combinations that either inhibit or limit the onset of this damaging disorder.
Figure 1 shows the historical development of lipodystrophy syndrome with respect to the introduction of monotherapy and combination therapy, with the consequent change in definition of the term lipodystrophy (revised from John et al 2001).
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
EMBALLAGE 2012
19-22 November 2012, Paris Nord Villepinte, France
EMBALLAGE has clearly delineated sectors to make the decision-maker’s task easier when visiting and to highlight all the industry’s know-how: machinery and packaging for the food and cosmetics sectors, health solutions and luxury packaging and containers, etc. Hence, EMBALLAGE provides a bespoke solution for each industry
More info >> |
|
 |
News and Press Releases |
 |
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.
More info >> |
|
|
